Internal Medicine

Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.

Grastek is the first sublingual allergy immunotherapy product to be approved for use in children as young as age 5.

Young fathers are at risk of developing depression during their children's formative years, a study published in Pediatrics concluded.

For psoriatic arthritis patients, foot pain and inflammation are tied to foot structure, according to research published in the April 2014 issue of Rheumatology.

Study results show testosterone therapy reduces total cholesterol, low-density lipoprotein cholesterol, and triglycerides while boosting high-density lipoprotein cholesterol.

An unexpectedly high number of cases of thrombotic microangiopathy has been reported in a small number of multiple sclerosis patients who are taking Rebif (interferon beta 1-alpha).

A tool for diagnosing and monitoring diabetes has received 510(k) clearance from the US Food and Drug Administration.

Yale University researchers have found a single "switch" in the brains of patients with epilepsy that determines whether an epileptic seizure will be mild or trigger a dangerous, debilitating loss of consciousness.

Noting the management and treatment of postherpetic neuralgia (PHN) are currently subpar in the primary care setting, 2 researchers recently reviewed and outlined key clinical considerations for the chronic neuropathic pain syndrome.

New blood pressure treatment guidelines announced in February 2014 by the Eighth Joint National Committee (JNC 8) may result in nearly 6 million American adults no longer requiring hypertension medications.

Although they offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation, effective use of the new anticoagulants requires careful patient selection.

Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.

Results from the NEED study show combination treatment with peginterferon alpha-2a and either adefovir or entecavir does not increase HBeAg seroconversion rate compared to monotherapy alone in patients with hepatitis B.

The ACC/AHA cholesterol guideline can be a powerful tool for making multifactorial measures of cardiovascular disease risk assessment, particularly in African American populations, but clinicians should be aware of its limitations.

Results from the SAPPHIRE-I trial show that Abbvie's 3D therapy produced 96% sustained viral response rates at 12 weeks in treatment-naive patient with genotype 1 hepatitis C.

Data from the PEARL-I trial of patients with hepatitis C genotype 4 show high rates of sustained virologic response at 12 weeks associated with combination treatment with ABT-450 (a protease inhibitor boosted by ritonavir) and ombitasvir.

An 8-week course of treatment with a fixed dose combination of ledipasvir plus sofosbuvir produced sustained virologic response in more than 90 percent of treatment-naïve patients with genotype 1 hepatitis C.

Clinicians should consider a patient's risk of hypoglycemia, the duration of time with the disease, age, comorbidities, vascular complications, and other factors when setting treatment goals.

With state-of-the-art treatment regimens for hepatitis C becoming more effective and easier to administer and monitor, care delivery will shift away from specialists to include more involvement by primary care physicians.

Several studies have shown good results with Roux-en-Y gastric bypass and laparoscopic gastric banding when combined with lifestyle modifications in severely overweight patients with type 2 diabetes.

Once confirmation of an asthma diagnosis is made, most primary care physicians can manage the condition and need refer only challenging cases to a pulmonologist.

Thorough screening, advance planning, careful medication selection, and caregiver education and training are the keys to effective management of patients with Alzheimer's disease.

According to research published in the Proceedings of the National Academy of Sciences, patients who are sensitive to d-amphetamine have a decreased likelihood of developing ADHD or schizophrenia.

Mitigating the risk of stroke, heart failure, and death when treating patients with atrial fibrillation requires a careful consideration of patient characteristics and management options.

Results from the ELECTRON-2 study presented at EASL 2014 show treatment with fixed-dose combo of sofosbuvir and ledipasvir produced sustained virologic response in three cohorts of patients.

Study of farnesoid-x receptor agonist demonstrates protective effects on bacterial translocation from the small intestine in rat model of cholestatic liver disease.

SAPPHIRE II trial results show sustained virologic response in 96% of treatment-experienced patients with genotype 1 hepatitis C who were treated with interferon-free, triple-drug regimen.

David J. Herman, MD, FACP, Senior Partner at ID Care in New Jersey, discusses strategies for the diagnosis and treatment of Lyme disease and other tick-borne infections.

Administering 2 so-called pregnancy hormones simultaneously in patients suffering from intractable pain may significantly reduce their opioid use, pain, and flare intensity.

IBS symptoms play a minor role, according to a study published in the American Journal of Gastroenterology, which asked patients to rate their overall health.